UAE Vaccines Market Analysis Report 2022 to 2030

UAE Vaccines Market Analysis

$ 3999

This report presents a strategic analysis of the UAE Vaccines Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the UAE vaccine market, offering unmatched value, accuracy, and expert insights.

ID: IN10AEPH025 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE

Buy Now

UAE Vaccines Market Executive Summary

While leveraging innovative strategies to increase economic growth and diversification, the UAE maintains its standing as one of the world's most competitive and advanced economies. The stability of the UAE's financial ecosystem and the resilience of the national economy are demonstrated by major economic development indicators. The UAE's federal budget for 2022-2030, with a total value of AED 290 billion, is the country's largest-ever expenditure budget. The budget prioritizes social development, government service improvement, federal project implementation, and economic development.

The UAE has a robust healthcare infrastructure as one of the most economically developed and diversified economies in the Middle East. The UAE government has made building a world-class healthcare infrastructure a primary priority, and as a result, the industry has grown and expanded tremendously in recent years. UAE’s Vision 2040 has healthcare as a priority sector for the UAE government, and the country will continue to be an attractive location for establishing a regional distribution center for healthcare services.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. Pharma revenues worldwide reached $1.42 trillion in 2021 due to the market's rapid growth over the previous two decades. With the introduction of new technology as well as more economical and effective manufacturing techniques, the pharmaceutical industry has experienced a significant transition. Additionally, the market growth has been positively driven by rising investment flow in this sector.

The never-ending trial-and-error process for developing effective treatments for diseases like malaria, HIV, and tuberculosis is one of the largest difficulties faced by organizations and businesses around the world. Due to an increase in the prevalence of bacterial and viral infectious diseases during the past several years, there has been an increase in the demand for immunizations. Vaccinations are basically given to people of all ages, which boosts their immune systems during the course of their lives and provides defence against various infectious diseases. Government agencies and pharmaceutical firms are working extremely hard to set up plans for the creation of treatments for these diseases.

Market Size and Key Findings

The Middle East and Africa Vaccines Market size is at around US $ 374.35 Bn in 2021 and is projected to reach US $ 533.85 Bn in 2030, exhibiting a CAGR of 6.5% during the forecast period.

UAE Vaccines Market Size (In USD Bn) (2021-2030F)

Market Dynamics

Market Growth Drivers Analysis

The possibility of newly emerging infectious diseases spreading quickly and causing pandemics over the world is a serious issue since people are interacting with wild animals more regularly, traveling much more frequently, and over much greater distances than they did in the past. Additionally, there is a chance that illnesses could spread as a result of the intentional introduction into populations of humans, animals, or plants for harmful objectives.

Market Restraints

The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. The development process takes 10 to 15 years and costs between USD 800 million - USD 1 billion. Additionally, because vaccine development has a low success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

Competitive Landscape

Key Players

The prominent players operating in this market include GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Sanofi SA (France), Pfizer, Inc. (US), Johnson & Johnson (US), CSL Limited (Australia), Novavax, Inc. (US), Panacea Biotec (India), Sinovac Biotech Ltd. (China) and Mitsubishi Tanabe Pharma Corporation (Japan)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vaccines Market Segmentation

By Technology (excluding COVID-19 vaccines) (Revenue, USD Billion):

Conjugate vaccines
Inactivated & Subunit vaccines
Live Attenuated vaccines
Recombinant vaccines
Toxoid vaccines
Viral vector vaccines

COVID-19 Vaccines Market, by Technology (Revenue, USD Billion):

mRNA vaccines
Viral Vector vaccines
Other vaccines (inactivated, recombinant, conjugate, subunit, peptide, and DNA vaccines)

By Type (Revenue, USD Billion):

Monovalent vaccines
Multivalent vaccines

By Disease Indication (Revenue, USD Billion):

Influenza
Pneumococcal diseases
Combination vaccines
HPV
Herpes Zoster
Meningococcal diseases
Rotavirus
MMR
Varicella
Hepatitis
DTP
Polio
COVID 19
Other disease indications (typhoid, dengue, yellow fever, tuberculosis, cancer, Japanese encephalitis, rabies and allergies)

By Route of Administration (Revenue, USD Billion):

Intramuscular & Subcutaneous administration
Oral administration
Other routes of administration (intranasal, intradermal, and percutaneous)

By End-user

Pediatric vaccines
Adult vaccines

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.